期刊文献+

气液相变型声学微粒的热相变特性评价 被引量:2

Preparation and evaluation of a phase shift lipid acoustic droplet
暂未订购
导出
摘要 目的 制备一种新型的具有气液相变特征的治疗型脂质超声微粒,并初步检测其物理特性,为进一步在体实验奠定基础。方法 在“脂氟显”配方的基础上,加入2%~5%的相变型物质全氟戊烷(DDFP),通过振荡、洗涤等一系列工序,制备具有气液相变特性的声学微粒。检测微粒大小、形态、分布、浓度、热膨胀等物理特性。结果 相变型声学微粒的粒径小于8脚,微粒浓度为6×10^9/ml。在常温下该气液相变声学微粒具有较好的稳定性,静置30min未见分层;升温至37℃时微粒平均直径膨胀约1倍,升温至50℃时微粒平均直径增大约5倍。结论 该相变型声学微粒在37℃以下物理性质稳定;37℃时粒径增大1倍,分布范围变化不大;其热相变启动于50℃以上,发生相变后微粒直径明显大于毛细血管内径。 Objective To prepare a new lipid- coated phase shift therapeatic acoustic droplet and evaluate the physical propercoes of the droplet in vitro. Methods The acoustic phase shift droplet was prepared by encapsulating 2% - 5% dodecafluoropentane (DDFP) into a kind of lipid microbubble. The droplet size, distribution and property of heat dilatability were assessed respectively by Coulter Miltisizer and optical microscopy. Results The size distribution of this lipid droplet ranged from 1 - 4 μm with all of the bubbles less than 8μm . The droplet concentration was 6 × 10^9/ml. The lipid droplet emulsion almost expanded to 2 times and 5 times in size under 37℃ and 50℃ respectively in vitro. Conclusion The acoustic phase shift droplet can double its diameter and is stable under 37℃. The thermal phase shift can be triggered above 50℃.
出处 《临床超声医学杂志》 2007年第11期641-643,共3页 Journal of Clinical Ultrasound in Medicine
基金 国家自然科学基金(30470468) 教育部留学归国启动基金[教外司留(2004)527号]
关键词 热相变 超声 造影剂 Phase shift Ultrasound Contrast medium
  • 相关文献

参考文献9

二级参考文献33

  • 1[1]Puls R,Hosten N,Lemke M,et al.Perfusion abnormalities of kidney parenchyma:microvascular imaging with contrast-enhanced color and power Doppler ultrasonography-preliminary results.J Ultrasound Med,2000,19(12):817-821
  • 2[2]Bauer A,Blomley M,Leen E,et al.Liver-specific imaging with SHU 563A:diagnostic potential of a new class of ultrasound contrast media.Eur-Radiol,1999,9 Suppl 3:S349-352
  • 3[3]Unger E C,McCreery T P,Sweitzer R H,et al.Acoustically active lipospheres containing paclitaxel:a new therapeutic ultrasound contrast agent.Invest Radiol,1998,33(12):886-892
  • 4[5]Correas JM, Bridal L,Lesavre A, et al.Ultrasound contrast age-nts:properties,principles of action,tolerance and artifacts.Eur-Radiol,2001,11(8):1316-1328
  • 5[6]Seidel G,Claassen L,Meyer K,et al.Evaluation of blood flow in the cerebral microcirculation:analysis of the refill kinetics during ultrasound contrast agent infusion.Ultrasound-Med-Biol,2001,27(8):1059-1064
  • 6[8]Kono Y,Moriyasu F,Nada T,et al.Ultrasonographic arterial por-tography with second harmonic imaging:evaluation of hepatic parenchymal enhancement with portal venous flow.J Ultrasound Med,1999,18:395-402
  • 7[9]Sirlin CB,Girard MS,Baker KG,et al.Effect of acquisition rate on liver and portal vein enhancement with microbubbles contrast.Ultrasound Med Biol,1999,25:331-338
  • 8Schneider M,Broillet A,Bussat P,et al.Gray-scale liver enhance-ment in VX2 tumors-bearing rabbits using BR14,a new ultrasonograhic contrast agent.Invest Radiol 1997,32:410-417
  • 9Forsberg F,Liu JB,Chiou HJ,et al.Comparison of fundamental and wideband harmonic contrast imaging of liver tumors.Ultrasonics,2000,38:110-113
  • 10Maruyama H,Matsutani S,Saisho H,et al.Grey-scale contrast en-hancement in rabbit liver with DMP 115 at different acoustic power levels.Ultrasound in Med.& Biol,1429-1438

共引文献74

同被引文献54

  • 1解立新,刘又宁.液体通气的临床应用进展[J].中华结核和呼吸杂志,2007,30(10):730-733. 被引量:5
  • 2van Vlerken LE, Amiji MM.Muhi-functional polymeric nanoparticles for tumour-targeted drug delivery.Expert Opin Drug Deliv, 2006, 3(2) :205-216.
  • 3Hemot S, Klibanov AL.Microbubbles in ultrasound-triggered drug and gene delivery.Adv Drug Deliv Rev, 2008,30(10) : 1153-1166.
  • 4Dtaz-L6pez R,Tsapis N,Fattal E.Liquid perfluorocarbons as contrast agents for ultrasonography and 19F-MRI.Pharm Res, 2010,27( 1 ): 1-16.
  • 5Duncan R, Sat - Klopsch YN, Burger AM, et al. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.Cancer Chemother Pharmacol,2013, 72(2) :417-427.
  • 6Crowder KC, Hughes MS, Marsh JN, et al. Sonic activationof molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery.Ultrasound Med Biol, 2005,31(12):1693-1700.
  • 7Soman NR, Marsh JN, Hughes MS, et al.Acoustic activation of targeted liquid perfluorocarbon nanoparticles does not compromise endothelial integrity.IEEE Trans Nanobioscience, 2006,5 (2) : 69-75.
  • 8Soman NR, Lanza GM, Heuser JM, et al.Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides.Nano Lett, 2008,8(4) : 1131-1136.
  • 9Soman NR, Baldwin SL, Hu G, et al.Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.J Clin Invest, 2009,119(9) : 2830-2842.
  • 10Partlow KC, Lanza GM, Wickline SA.Exploiting lipid raft transport with membrane targeted nanoparticles:A strategy for cytosolic drug delivery.Biomaterials, 2008,29( 23 ) : 3367-3375.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部